scispace - formally typeset
Y

Ying Xu

Researcher at Chengdu Medical College

Publications -  56
Citations -  446

Ying Xu is an academic researcher from Chengdu Medical College. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 8, co-authored 22 publications receiving 177 citations.

Papers
More filters
Journal ArticleDOI

Characterization of carbapenem-resistant Acinetobacter baumannii isolates in a Chinese teaching hospital.

TL;DR: It is indicated that rational application of antibiotics is indispensable for minimizing widespread of drug resistance in CRAB, and CC92 A. baumannii carrying OXA-23 is a major drug-resistant strain spreading in China.
Journal ArticleDOI

Serum klotho protein levels and their correlations with the progression of type 2 diabetes mellitus

TL;DR: Serum levels of α-KLotho and β-Klotho are down-regulated in patients with type 2 diabetes mellitus, and the positive correlation of α/ β/Kloths levels indicates that they might have similar mechanisms in T2DM.
Journal ArticleDOI

miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549.

TL;DR: In this article, the effect of miR-324-3p on lung adenocarcinoma cell line A549 resistant to cis-diamminedichloroplatinum II (DDP), aka cisplatin was investigated.
Journal ArticleDOI

Bixin Attenuates Experimental Autoimmune Encephalomyelitis by Suppressing TXNIP/NLRP3 Inflammasome Activity and Activating NRF2 Signaling.

TL;DR: It is found that bixin significantly improved the symptoms and pathology in EAE mice, reduced the release of inflammatory cytokines TNF-α,IL-6, IL-8, Il-17, and IFN-γ, and increased the expression of the anti-inflammatory cytokine IL-10, and taken together these results indicate thatbixin is a promising therapeutic candidate for treatment of MS.
Journal ArticleDOI

PLEK2 mediates metastasis and vascular invasion via the ubiquitin-dependent degradation of SHIP2 in non-small cell lung cancer

TL;DR: PLEK2 could be a novel prognostic marker and potential therapeutic target for NSCLC metastasis and vascular invasion, and is found to directly interact with SHIP2 and target it for ubiquitination and degradation inNSCLC cells.